Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Celgene Corporation CELG

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U


NDAQ:CELG - Post by User

Bullboard Posts
Post by stockman89on Apr 22, 2009 10:39pm
703 Views
Post# 15938011

20 Stocks With High Net Cash

20 Stocks With High Net Cash

Companies with large amounts of cash have a greater ability to withstand the pressures of a recession and are well positioned to expand their businesses through takeovers if such opportunities present themselves. However, we believe that an analysis of a firm’s cash position would be incomplete without also considering their debt burden. As a result, we have conducted a study of firms with large cash on hand and subtracted total liabilities to determine their net cash position.

The list below shows 20 of the largest firms with high net cash.

20 Stocks With High Net Cash*




*Cash & Equivalents + Short-Term Investments - Total Liabilities
**Our Proprietary Recommendations

These stocks should not be blindly purchased. Rather, investors can use this list as a starting point. Ideally, investors should try to determine what growth opportunities are available to these firms if that is possible. If growth opportunities exist (i.e. there are potential takeover targets) within their respective industries, then the excess cash (possibly combined with additional debt) can be put to good use. In addition, investors should consider valuations, qualitative factors along with industry competition.

The fourth column in the table above shows our Ranking System’s buy/sell recommendations (for more information about our Ranking System please visit our website). According to our Ranking System AAPL, CSCO, QCOM, FRX, ADBE should outperform the broad market over the next 3-12 months.

Happy Trading

https://www.SuperStockScreener.com

Bullboard Posts